Clinical characterization and molecular mechanisms of statin myopathy

References

• Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20 536 high-risk individuals: a randomised placebo-controlled trial. Lancet360(9326), 7–22 (2002).
   PubMed Web of Science ®Google Scholar
• Sever PS, Dahlof B, Poulter NR et al. Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial – Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trial. Lancet361(9364), 1149–1158 (2003).
   PubMed Web of Science ®Google Scholar
• Ford ES, Mokdad AH, Giles WH, Mensah GA. Serum total cholesterol concentrations and awareness, treatment, and control of hypercholesterolemia among US adults: findings from the National Health and Nutrition Examination Survey, 1999 to 2000. Circulation107(17), 2185–2189 (2003).
   PubMed Web of Science ®Google Scholar
• Maggini M, Raschetti R, Traversa G et al. The cerivastatin withdrawal crisis: a “post-mortem” analysis. Health Policy69(2), 151–157 (2004).
   PubMed Web of Science ®Google Scholar
• Pasternak RC, Smith SC Jr, Bairey-Merz CN et al. ACC/AHA/NHLBI clinical advisory on the use and safety of statins. Stroke33(9), 2337–2341 (2002).
   PubMed Web of Science ®Google Scholar
• McKenney JM, Davidson MH, Jacobson TA, Guyton JR. Final conclusions and recommendations of the National Lipid Association Statin Safety Assessment Task Force. Am. J. Cardiol.97(8A), 89C–94C (2006).
   PubMed Web of Science ®Google Scholar
• Law M, Rudnicka AR. Statin safety: a systematic review. Am. J. Cardiol.97(8A), 52C–60C (2006).
   PubMed Web of Science ®Google Scholar
• Gaist D, Rodriguez LA, Huerta C, Hallas J, Sindrup SH. Lipid-lowering drugs and risk of myopathy: a population-based follow-up study. Epidemiology12(5), 565–569 (2001).
   PubMed Web of Science ®Google Scholar
• Shanahan RL, Kerzee JA, Sandhoff BG, Carroll NM, Merenich JA. Low myopathy rates associated with statins as monotherapy or combination therapy with interacting drugs in a group model health maintenance organization. Pharmacotherapy25(3), 345–351 (2005).
   PubMed Web of Science ®Google Scholar
• Bruckert E, Hayem G, Dejager S, Yau C, Begaud B. Mild to moderate muscular symptoms with high-dosage statin therapy in hyperlipidemic patients – the PRIMO Study. Cardiovasc. Drugs Ther.19(6), 403–414 (2005).
   PubMed Web of Science ®Google Scholar
• Scott RS, Lintott CJ, Wilson MJ. Simvastatin and side effects. NZ Med. J.104(924), 493–495 (1991).
   PubMed Web of Science ®Google Scholar
• Kordas KC, Phillips PS, Golomb BA. Clinical characteristics of 1053 patients with statin-associated muscle complaints. Arterioscler. Thromb. Vasc. Biol.24, e133 (2004).
   Google Scholar
• Hansen KE, Hildebrand JP, Ferguson EE, Stein JH. Outcomes in 45 patients with statin-associated myopathy. Arch. Intern. Med.165(22), 2671–2676 (2005).
   PubMed Web of Science ®Google Scholar
• Rosenson RS. Current overview of statin-induced myopathy. Am J. Med.116(6), 408–416 (2004).
   PubMed Web of Science ®Google Scholar
• Vladutiu GD, Simmons Z, Isackson PJ et al. Genetic risk factors associated with lipid-lowering drug-induced myopathies. Muscle Nerv.34(2),153–162 (2006).
   PubMed Web of Science ®Google Scholar
• Brewer HB Jr. Benefit–risk assessment of rosuvastatin 10 to 40 milligrams. Am. J. Cardiol.92(4B), 23K–29K (2003).
   PubMed Web of Science ®Google Scholar
• Prueksaritanont T, Tang C, Qiu Y, Mu L, Subramanian R, Lin JH. Effects of fibrates on metabolism of statins in human hepatocytes. Drug Metab. Dispos.30(11), 1280–1287 (2002).
   PubMed Web of Science ®Google Scholar
• Jones PH, Davidson MH. Reporting rate of rhabdomyolysis with fenofibrate + statin versus gemfibrozil + any statin. Am. J. Cardiol.95(1), 120–122 (2005).
   PubMed Web of Science ®Google Scholar
• Hsiang B, Zhu Y, Wang Z et al. A novel human hepatic organic anion transporting polypeptide (OATP2): identification of a liver-specific human organic anion transporting polypeptide and identification of rat and human hydroxymethylglutaryl-CoA reductase inhibitor transporters. J. Biol. Chem.274(52), 37161–37168 (1999).
   PubMed Web of Science ®Google Scholar
• Nishizato Y Ieiri I, Suzuki H et al. Prolymorphisms of OATP-C (SLC21A6) and OAT3 (SLC22A8) genes: consequences for pravastatin pharmacokinetics. Clin. Pharmacol. Ther.73(6), 554–565 (2003).
   PubMed Web of Science ®Google Scholar
• Bottorff MB. Statin safety and drug interactions: clinical implications. Am. J. Cardiol.97(8A), 27C–31C (2006).
   PubMed Web of Science ®Google Scholar
• Davidson MH, Robinson JG. Safety of aggressive lipid management. J. Am. Coll. Cardiol.49(17), 1753–1762 (2007).
   PubMed Web of Science ®Google Scholar
• Ballantyne CM, Corsini A, Davidson MH et al. Risk for myopathy with statin therapy in high-risk patients. Arch. Intern Med.163(5), 553–564 (2003).
   PubMed Web of Science ®Google Scholar
• Harper CR, Jacobson TA. Managing dyslipidemia in the CKD patient. J. Am. Coll. Cardiol. (2008) (In Press).
   PubMedGoogle Scholar
• Melli G, Chaudhry V, Cornblath DR. Rhabdomyolysis. An evaluation of 475 hospitalized patients. Medicine.84(6), 377–385 (2005).
   PubMed Web of Science ®Google Scholar
• Phillips PS, Haas RH. Observations from a statin myopathy clinic. Arch. Intern. Med.166(11), 1232–1233 (2006).
   PubMedGoogle Scholar
• Phillips PS, Haas RH, Bannykh S et al. Statin-associated myopathy with normal creatine kinase levels. Ann. Intern. Med.137(7), 581–585 (2002).
   PubMed Web of Science ®Google Scholar
• Guijarro C, Blanco-Colio LM, Ortego M et al. 3-hydroxy-3-methylglutaryl coenzyme A reductase and isoprenylation inhibitors induce apoptosis of vascular smooth muscle cells in culture. Circ. Res.83(5), 490–500 (1998).
   PubMed Web of Science ®Google Scholar
• Thompson PD, Clarkson P, Karas RH. Statin-associated myopathy. JAMA289(13), 1681–1690 (2003).
   PubMed Web of Science ®Google Scholar
• Harper CR, Jacobson TA. The broad spectrum of statin myopathy: from myalgia to rhabdomyolysis. Curr. Opin. Lipidol.18(4), 401–408 (2007).
   PubMed Web of Science ®Google Scholar
• Mach F. Statins as immunomodulatory agents. Circulation109(21 Suppl. II), 15–17 (2004).
   Google Scholar
• Kwak BR, Mulhaupt F, Mach F. Atherosclerosis: anti-inflammatory and immunomodulatory activities of statins. Autoimmun. Rev.2(6), 332–338 (2003).
   PubMed Web of Science ®Google Scholar
• Sadeghi MM, Tiglio A, Sadigh K et al. Inhibition of interferon-gamma mediated microvascular endothelial cell major histocompatibility complex class II gene activation by HMG-CoA reductase inhibitors. Transplantation71(9), 1262–1268 (2001).
   PubMed Web of Science ®Google Scholar
• Needham M, Fabian V, Knezevic W, Panegyres P, Zilko P, Mastaglia FL. Progressive myopathy with up-regulation of MHC-1 associated with statin therapy. Neuromuscul. Disord.17(2), 194–200 (2007).
   PubMed Web of Science ®Google Scholar
• Chapman MJ, Carrie A. Mechanisms of statin-induced myopathy: a role for the ubiquitin-proteasome pathway? Arterioscler. Thromb. Vasc. Biol.25(12), 2441–2444 (2005).
   PubMed Web of Science ®Google Scholar
• Urso ML, Clarkson PM, Hittel D, Hoffman EP, Thompson PD. Changes in ubiquitin proteasome pathway gene expression in skeletal muscle with exercise and statins. Atheroscler. Thromb. Vasc. Biol.25(12), 2560–2566 (2005).
   PubMed Web of Science ®Google Scholar
• Hanai J, Cao P, Tanksale P et al. The muscle-specific ubiquitin ligase atrogin-1/MAFbx mediates statin-induced muscle toxicity. J. Clin. Invest.117(12), 3940–3951 (2007).
   PubMed Web of Science ®Google Scholar
• Oh J, Ban MR, Miskie BA, Pollex RL, Hegele RA. Genetic determinants of statin intolerance. Lipids Health Dis.6(7), (2007).
   PubMedGoogle Scholar
• Phillips PS, Phillips CT, Sullivan MJ, Naviaux RK, Haas RH. Statin myotoxicity is associated with changes in the cardiopulmonary function. Atherosclerosis117(1),183–188 (2004).
   Google Scholar
• Baer AN, Wortmann RL. Myotoxicity associated with lipid-lowering drugs. Curr. Opin. Rheumatol.19(1), 67–73 (2007).
   PubMed Web of Science ®Google Scholar
• Marcoff L, Thompson PD. The role of coenzyme Q10 in statin-associated myopathy. J. Am. Coll. Cardiol.49(23), 2231–2237 (2007).
   PubMed Web of Science ®Google Scholar
• Littarru GP, Langsjoen P. Coenzyme Q10 and statins: biochemical and clinical implications. Mitochondrion.7(Suppl.), S168–S174 (2007).
   PubMed Web of Science ®Google Scholar
• Caso G, Kelly P, McNurlan MA, Lawson WE. Effect of coenzyme Q10 on myopathic symptoms in patients treated with statins. Am. J. Cardiol.99(10), 1409–1412 (2007).
   PubMed Web of Science ®Google Scholar
• Paiva H, Thelen KM, VanCoster R et al. High-dose statins and skeletal muscle metabolism in humans: a randomized controlled trial. Clin. Pharmacol. Ther.78(1), 60–68 (2005).
   PubMed Web of Science ®Google Scholar
• Laaksonen R, Jokelainen K, Sahi Tikkanen MJ, Himsberg JJ . Decreases in serum ubiquinone concentrations do not result in reduced levels in muscle tissue during short-term simvastatin treatment in himans. Clin. Pharmacol. Ther.57(1), 62–66 (1995).
   PubMed Web of Science ®Google Scholar
• Langsjoen PH, Langsjoen AM. Coenzyme Q10 in CVD with emphases on heart failure and myocardial ischaemia. Asia Pacific Heart J.7(3), 160–168 (1998).
   Google Scholar
• Pepe S, Marasco SF, Haas SJ, Sheeran FL, Krum H, Rosenfeldt FL. Coenzyme Q10 in cardiovascular disease. Mitochondrion7(Suppl.), S154–S167 (2007).
   PubMed Web of Science ®Google Scholar
• Crane FL. Biochemical functions of coenzyme Q10. J. Am. Coll. Nutr.20(6), 591–598 (2001).
   PubMed Web of Science ®Google Scholar
• Horvath R, Schneiderat P, Schoser BG et al. Coenzyme Q10 deficiency and isolated myopathy. Neurology66(2), 253–255 (2006).
   PubMed Web of Science ®Google Scholar
• Thibault A, Samid D, Tompkins AC et al. Phase I study of lovastatin, an inhibitor of the mevalonate pathway, in patients with cancer. Clin. Cancer Res.2(3), 483–491 (1996).
   PubMed Web of Science ®Google Scholar
• Young JM, Florkowski CM, Molyneux SL et al. Effect of coenzyme Q10 supplementation on simvastatin-induced myalgias. Am. J. Cardiol.100(9), 1400–1403 (2007).
   PubMed Web of Science ®Google Scholar
• Mastaglia FL. Drug induced myopathies. Practical Neurology6(1), 4–13 (2006).
   Google Scholar
• Beetham R. Biochemical investigation of suspected rhabdomyolysis. Ann. Clin. Biochem.37(Pt 5), 581–587 (2000).
   PubMed Web of Science ®Google Scholar
• Kearns AK, Bilbie CL, Clarkson PM et al. The creatine kinase response to eccentric exercise with atorvastatin 10 mg or 80 mg. Atherosclerosis (2008) (Epub ahead of print).
   PubMedGoogle Scholar
• Flint OP, Masters BA, Gregg RE, Durham SK. Inhibition of cholesterol synthesis by squalene synthase inhibitors does not induce myotoxicity in vitro. Toxicol. Appl. Pharmacol.145(1), 91–98 (1997).
   PubMed Web of Science ®Google Scholar
• Baker SK. Molecular clues into the pathogenesis of statin-mediated toxicity. Muscle Nerve31(5), 572–580 (2005).
   PubMed Web of Science ®Google Scholar
• de Lemos JA, Blazing MA, Wiviott SD et al. Early intensive vs a delayed conservative simvastatin strategy in patients with acute coronary syndromes: phase Z of the A to Z trial. JAMA292(11), 1307–1316 (2004).
   PubMed Web of Science ®Google Scholar
• Alsheikh-Ali AA, Maddukuri PV, Han H, Karas RH. Effect of the magnitude of lipid lowering on risk of elevated liver enzymes, rhabdomyolysis, and cancer. J. Am. Coll. Cardiol.50(5), 409–418 (2007).
   PubMed Web of Science ®Google Scholar
• Jones PH, McKenney JM, Karalis DG, Downey J. Comparison of the efficacy and safety of atorvastatin initiated at different starting doses in patients with dyslipidemia. Am. Heart J.149(1), e1–e8 (2005).
   Web of Science ®Google Scholar
• Thompson PD, Clarkson PM, Rosenson RS; The National Lipid Association Statin Safety Task Force Muscle Safety Expert Panel. An assessment of statin safety by muscle experts. Am. J. Cardiol.97(8A), 69C–76C (2006).
   PubMed Web of Science ®Google Scholar
• Huerta-Alardin AL, Varon J, Marik PE. Bench-to-bedside review: rhabdomyolysis – an overview for clinicians. Crit. Care9(2), 158–169 (2005).
   PubMed Web of Science ®Google Scholar
• Stein EA, Ballantyne CM, Windler E et al. Efficacy and tolerability of fluvastatin XL 80 mg alone, ezetimibe alone and the combination of fluvastatin XL 80 mg with ezetimibe, in patients with a history of muscle-related side effects with other statins. Am. J. Cardiol.101(4), 490–496 (2008).
   PubMed Web of Science ®Google Scholar
• Havranek JM, Wolfsen AR, Warnke GA, Phillips PS. Monotherapy with ezetimibe causing myopathy. Am. J. Med.119(3), 285–286 (2006).
   PubMed Web of Science ®Google Scholar
• Jacobson TA, Armani A, McKenney JM, Guyton JR. Safety considerations with gastrointestinally active lipid-lowering drugs. Am. J. Med.99(6A), 47C–55C (2007).
   Google Scholar
• Davidson MH, Armani A, McKenney JM, Jacobson TA. Safety considerations with fibrate therapy. Am. J. Cardiol.99(6A), 3C–18C (2007).
   PubMed Web of Science ®Google Scholar
• Jacobson TA. Toward pain-free statin prescribing: a clinical algorithm for diagnosis and management of myalgia. 83(6), 687–700 (2008).
   Google Scholar